Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Van Gogh-PE: SR34006 vs Standard Therapy in Acute PE
NCT00062803Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of idraparinux in pulmonary embolism (PE) (2 arms), sponsored by Sanofi. Primary endpoint: Symptomatic recurrent pulmonary embolism or deep vein thrombosis within 3 months. Started Jun 2003; status: completed.
02
Drugs
idraparinux
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00062803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062803.